Stock Research: bioMerieux

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

bioMerieux

ENXTPA:BIM FR0013280286
90
  • Value
    81
  • Growth
    67
  • Safety
    Safety
    37
  • Combined
    81
  • Sentiment
    83
  • 360° View
    360° View
    90
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

BioMerieux SA specializes in in-vitro diagnostics for medical and industrial applications. The company operates in the medical diagnostics and industrial analysis industries. It has subsidiaries in France, Germany, Austria, and other countries. In the last fiscal year, the company had a market cap of $16,227 million, profits of $2,294 million, and revenue of $4,120 million, with 14,754 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 90 (better than 90% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock bioMerieux are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for bioMerieux. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. The consolidated Safety Rank at 81 means that the company has a financing structure that is safer than 81% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 83, which means that professional investors are more optimistic about the stock than for 83% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 37, meaning that the share price of bioMerieux is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 63% of alternative stocks in the same industry. ...read more

more
Index
CAC All
SBF 120
Human Rights
Recycling
SDG 10
SDG 12
SDG 13
SDG 3
SDG 8
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 62 67 77
Growth
67 70 31 25
Safety
Safety
81 93 90 85
Sentiment
83 88 65 79
360° View
360° View
90 100 86 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
45 47 59 69
Opinions Change
50 68 61 50
Pro Holdings
n/a 87 90 17
Market Pulse
88 73 18 92
Sentiment
83 88 65 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 62 67 77
Growth
67 70 31 25
Safety Safety
81 93 90 85
Combined
81 100 86 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
21 40 47 50
Price vs. Earnings (P/E)
44 52 52 72
Price vs. Book (P/B)
40 44 52 61
Dividend Yield
45 53 51 43
Value
37 62 67 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
45 60 42 16
Profit Growth
60 73 37 64
Capital Growth
39 56 34 37
Stock Returns
91 64 57 35
Growth
67 70 31 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
76 72 78 65
Refinancing
47 45 43 40
Liquidity
89 92 92 94
Safety Safety
81 93 90 85

Similar Stocks

Discover high‑ranked alternatives to bioMerieux and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Societe Generale

ENXTPA:GLE
Country: France
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Savencia

ENXTPA:SAVE
Country: France
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Drägerwerk

XTRA:DRW3
Country: Germany
Industry: Health Care Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.